- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Stevenage Bioscience Catalyst Wins the UK’s PING Innovation Award
The UK’s Stevenage Bioscience Catalyst,1 a globally recognized cluster for therapeutic research and development providing support for translation and commercialization of innovative new medicines, won the 2021 PING Innovation Award in November.
The PING Innovation Award2 recognizes individuals and organizations whose innovative ideas, products, services or processes in the pharma sector are making a positive impact on people‘s lives.
Dr. Sally Ann Forsyth OBE, CEO of Stevenage Bioscience Catalyst commented, “It is a pleasure to receive this award on behalf of Stevenage Bioscience Catalyst. On campus we have created a vibrant ecosystem that brings academics, entrepreneurs and major corporates together in a collaborative and supportive environment that helps companies to grow. I would like to thank VWV for the award, all our partners and collaborators who have provided outstanding support and the SBC team for their tireless efforts to create the globally recognized cluster we see today.”
Paul Gershlick, Chair of PING and Head of Pharmaceuticals and Life Sciences at the law firm VWV, praised the winner. "We heard a lot at the recent 2021 PING Conference — led by VWV in conjunction with IQVIA3 and supported by Hertfordshire Local Enterprise Partnership4 — about innovation and collaboration, and Stevenage Bioscience Catalyst ticks both boxes. The campus was certainly innovative when it opened, and its building and design were made with collaboration in mind. What it has achieved in a relatively short space of time makes it a very worthy winner — not only for being instrumental in the location of the pioneering Cell and Gene Therapy Catapult, but also for helping other exciting early-stage life sciences companies build the platform to grow and develop.”
Previous winners of the PING Innovation Award include Cell and Gene Therapy Catapult, Dr Harry Destecroix of Ziylo, Paul Strickland Scanner Centre, Sigma Pharmaceuticals Plc, the University of Hertfordshire, Proteus Digital Health and Leslie Morgan of Durbin Plc.
Read more about the PING Innovation Award 2021 winner here.
Notes
- https://www.stevenagecatalyst.com
- https://www.vwv.co.uk/law-sector/pharmaceutical-law-life-sciences/ping
- https://www.iqvia.com/locations/united-kingdom
- https://www.hertfordshirelep.com
Contact details
Main author:
Name: Paul Gershlick
Job title: PING Chair, Partner and Head of Pharmaceuticals and Life Sciences sector
Address: VWV Watford - 45 Clarendon Rd, Watford WD17 1SZ
Telephone: 01923 919 320
Mobile: 07795 570 072
Email: pgershlick@vwv.co.uk
Author support:
Name: Sandeep Saib
Job title: Marketing and Business Development Executive
Address: VWV London - 24 King William Street, London EC4R 9AT
Telephone: 020 7665 0964
Email: ssaib@vwv.co.uk
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
